leisure time -WSS

leisure time

author：leisure time 2025-10-01 16:38:28 - browse：479

Adam's take main illustration — Molly Ferguson/STAT

Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Readout Newsletter: Illumina, CRISPR, Regeneron

WSS

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Erich Jarvis studies song birds to learn about human stuttering

Ionis drug prevents swelling attacks due to hereditary angioedema

Cancer, immunology, HIV research ensnared in fetal tissue politics

FDA's Pazdur wants cancer trials to range beyond China alone

focus

leisure time

Wikipedia

Supreme Court strikes down use of affirmative action

Innovation in antibiotics is ailing. 'Brain drain' may kill it

23andMe had bad news about my health. I wish a person had delivered it

Ultragenyx gene therapy for rare liver ailment succeeds in late

Affirmative action in medical school literally saved lives

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Activists slam private health insurers over coverage restrictions

Diabetes management: Digital health tools fall short, study says

Sports medicine is finally prioritizing gender equality

Chinese researcher claims birth of first gene

hotspot

Letters to First Opinion on caregivers, digital health, and more

Texas board proposes rules on abortion law emergency exemption

Mirador, a new biotech startup, launches with $400 million

Readout Newsletter: Illumina, CRISPR, Regeneron

Texas board proposes rules on abortion law emergency exemption

U.K. officials, researchers try to ease path for bespoke genetic treatments

focus

explore

focus

explore